Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924849 | 0.87 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3 | |
| SCHEMBL926179 | 0.86 | LMNA (0.57) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 | |
| SCHEMBL4214047 | 0.77 | PIK3CG (0.59) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 | |
| SCHEMBL4213933 | 0.77 | PIK3CG (0.70) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 | |
| SCHEMBL4523302 | 0.74 | MEN1 (0.80) | PIK3CGMEN1POLBKMT2A | |
| SCHEMBL927884 | 0.73 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3 | |
| SCHEMBL926639 | 0.71 | PIK3CG (0.62) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 | |
| SCHEMBL925082 | 0.71 | PIK3CG (0.50) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 | |
| SCHEMBL926185 | 0.70 | PIK3CG (0.57) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 | |
| SCHEMBL4207312 | 0.69 | PIK3CG (0.57) | PIK3CDPIK3CGPIK3CBPIK3CAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | KDM1A 3446/4885PIK3CD 6/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.